Document Classification

Section Type: RESULTS

Text: Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3. 7 percentage points ; P < 0. 001) and with an increased incidence of diabetes diagnoses (absolute excess, 1. 3 percentage points ; P < 0. 001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1. 0 percentage point ; P < 0. 001), musculoskeletal system (absolute excess, 0. 7 percentage points ; P < 0. 001), skin (absolute excess, 0. 3 percentage points ; P = 0. 003), and unexpectedly, infection (absolute excess, 1. 4 percentage points ; P < 0. 001) and bleeding (absolute excess, 0. 7 percentage points ; P < 0. 001).